BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9448878)

  • 1. Hyperprolactinaemia in males: a heterogeneous disorder.
    Walsh JP; Pullan PT
    Aust N Z J Med; 1997 Aug; 27(4):385-90. PubMed ID: 9448878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
    Greenman Y; Tordjman K; Stern N
    Clin Endocrinol (Oxf); 1998 May; 48(5):547-53. PubMed ID: 9666865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size.
    van 't Verlaat JW; Croughs RJ
    Clin Endocrinol (Oxf); 1991 Mar; 34(3):175-8. PubMed ID: 2036725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy.
    Howlett TA; Wass JA; Grossman A; Plowman PN; Charlesworth M; Touzel R; Rees LH; Savage MO; Besser GM
    Clin Endocrinol (Oxf); 1989 Feb; 30(2):131-40. PubMed ID: 2612015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy.
    Tyson D; Reggiardo D; Sklar C; David R
    Am J Dis Child; 1993 Oct; 147(10):1057-61. PubMed ID: 8213676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for macroprolactinaemia and pituitary imaging studies.
    Hauache OM; Rocha AJ; Maia AC; Maciel RM; Vieira JG
    Clin Endocrinol (Oxf); 2002 Sep; 57(3):327-31. PubMed ID: 12201824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
    Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
    Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
    Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
    Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone secretion elicited by GHRH, GHRP-6 or GHRH plus GHRP-6 in patients with microprolactinoma and macroprolactinoma before and after bromocriptine therapy.
    Popovic V; Simic M; Ilic L; Micic D; Damjanovic S; Djurovic M; Obradovic S; Dieguez C; Casanueva F
    Clin Endocrinol (Oxf); 1998 Jan; 48(1):103-8. PubMed ID: 9509075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a long-acting injectable form of bromocriptine in patients with prolactin and growth hormone secreting macroadenomas.
    Tsagarakis S; Tsiganou E; Tzavara I; Nikolou H; Thalassinos N
    Clin Endocrinol (Oxf); 1995 Jun; 42(6):593-9. PubMed ID: 7634499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Macroadenoma of the pituitary gland with moderate hyperprolactinaemia].
    Harms E; Siggelkow H; Buchfelder M; Saeger W; Hüfner M
    Dtsch Med Wochenschr; 2003 Mar; 128(13):667-70. PubMed ID: 12660899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
    Doknic M; Pekic S; Zarkovic M; Medic-Stojanoska M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2002 Jul; 147(1):77-84. PubMed ID: 12088923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Control of prolactin-secreting macroadenomas with parenteral, long-acting bromocriptine in 30 patients treated for up to 3 years.
    Haase R; Jaspers C; Schulte HM; Lancranja I; Pfingsten H; Orri-Fend M; Reinwein D; Benker G
    Clin Endocrinol (Oxf); 1993 Feb; 38(2):165-76. PubMed ID: 8435897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bromocriptine treatment of males with pituitary tumours, hyperprolactinaemia, and hypogonadism.
    Nagulesparen M; Ang V; Jenkins JS
    Clin Endocrinol (Oxf); 1978 Jul; 9(1):73-9. PubMed ID: 679504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.